Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP116766.RACFGYEsV3Mx30Od6lKM9fwAxsuS35o_nW9TM0ZH1-mkg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP116766.RACFGYEsV3Mx30Od6lKM9fwAxsuS35o_nW9TM0ZH1-mkg130_assertion type Assertion NP116766.RACFGYEsV3Mx30Od6lKM9fwAxsuS35o_nW9TM0ZH1-mkg130_head.
- NP116766.RACFGYEsV3Mx30Od6lKM9fwAxsuS35o_nW9TM0ZH1-mkg130_assertion description "[LOH of 1p in the heterogeneous population of malignant gliomas may be one of the important factors besides MGMT methylation that predict better outcome in patients treated with TMZ.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP116766.RACFGYEsV3Mx30Od6lKM9fwAxsuS35o_nW9TM0ZH1-mkg130_provenance.
- NP116766.RACFGYEsV3Mx30Od6lKM9fwAxsuS35o_nW9TM0ZH1-mkg130_assertion evidence source_evidence_literature NP116766.RACFGYEsV3Mx30Od6lKM9fwAxsuS35o_nW9TM0ZH1-mkg130_provenance.
- NP116766.RACFGYEsV3Mx30Od6lKM9fwAxsuS35o_nW9TM0ZH1-mkg130_assertion SIO_000772 17721049 NP116766.RACFGYEsV3Mx30Od6lKM9fwAxsuS35o_nW9TM0ZH1-mkg130_provenance.
- NP116766.RACFGYEsV3Mx30Od6lKM9fwAxsuS35o_nW9TM0ZH1-mkg130_assertion wasDerivedFrom lhgdn-20090331 NP116766.RACFGYEsV3Mx30Od6lKM9fwAxsuS35o_nW9TM0ZH1-mkg130_provenance.
- NP116766.RACFGYEsV3Mx30Od6lKM9fwAxsuS35o_nW9TM0ZH1-mkg130_assertion wasGeneratedBy ECO_0000203 NP116766.RACFGYEsV3Mx30Od6lKM9fwAxsuS35o_nW9TM0ZH1-mkg130_provenance.